Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective A  

$1,924,932.00
Fiscal Year: 2010

Yellow dot: Objective has some degree of funding, but less than the recommended amount.4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.

Download 2010 Question 4: Long-term Objective A projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Clinical Trials Network Staff Member Autism Speaks (AS)
Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex Sahin, Mustafa Childrens Hospital Boston
The effects of oxytocin on complex social cognition in autism spectrum disorders Bartz, Jennifer Mount Sinai School of Medicine
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders Swedo, Susan National Institutes of Health
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes Reiss, Allan Stanford University
Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine Arnold, L. Eugene The Ohio State University
ACE Center: Understanding repetitive behavior in autism McCracken, James University of California, Los Angeles
ACE Center: The pharmacogenetics of treatment for insistence sameness in autism Owley, Thomas University of Illinois at Chicago
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Stein, Peter University of Medicine & Dentistry of New Jersey
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Johnson, William University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Novotny, Sherie University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School